Pulmonary Function Testing Systems Market

Pulmonary Function Testing Systems Market Size

The global pulmonary function testing systems market size was valued at USD 2.9 billion in 2024 and is expected to exhibit growth at a CAGR of 6.6% from 2025 to 2034 period. The high market progression can be attributed to the technological advancements in testing systems, growing geriatric population, increased awareness about early diagnosis, and expanding healthcare infrastructure.

Moreover, the rising prevalence of respiratory diseases, including chronic obstructive pulmonary disease (COPD), asthma, and lung cancer, drives the adoption of pulmonary function testing systems. For instance, according to the World Health Organization (WHO), COPD affected 391 million people globally in 2022, while asthma impacted 339 million individuals. Similarly, the Centers for Disease Control and Prevention (CDC) reported that lung cancer cases in the U.S. increased by 2.3% annually between 2021 and 2023. These testing systems are essential for early diagnosis and continuous monitoring of respiratory conditions, enabling effective disease management.

Furthermore, innovations in pulmonary function testing systems, including portable devices, advanced spirometers, and integrated software for precise analysis, are driving market growth. These advancements improve diagnostic accuracy, ease of use, and patient comfort, encouraging wider adoption.

Pulmonary function testing systems are a set of medical devices and equipment used to evaluate the respiratory function of an individual. These systems measure various aspects of lung function, including the volume of air a person can inhale and exhale, the speed of the breath, and the efficiency of the lungs in exchanging gases.

Pulmonary Function Testing Systems Market Trends

The market is witnessing significant growth driven by surging demand for integrated advanced technologies, rising use in occupational health and industrial applications, and increasing focus on digital health solutions.

• Further, there is a growing demand for portable pulmonary function testing devices suitable for home use. These devices allow patients to monitor their respiratory health conveniently and continuously, meeting the needs of individuals with chronic respiratory conditions and supporting telehealth solutions.
  
• Additionally, the market is witnessing the adoption of advanced technologies such as artificial intelligence in healthcare, machine learning, and the Internet of Things (IoT) in healthcare. These innovations enhance diagnostic precision, automate data analysis, and provide real-time monitoring, ultimately improving the efficiency of pulmonary function testing systems and contributing to the increasing market demand.
  

Pulmonary Function Testing Systems Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on product, the market is classified into handheld and tabletop. The handheld segment generated the highest revenue of USD 1.7 billion in 2024.

• Handheld pulmonary function testing systems are compact, easy to use, and ideal for point-of-care settings and home monitoring. Their portability allows healthcare providers and patients to perform tests in various environments, which enhances their adoption.
  
• Moreover, these devices are more affordable than full-scale laboratory-based pulmonary function testing systems. This cost advantage makes them accessible to small clinics, primary care centers, and patients in resource-limited settings.
  

Based on test type, the pulmonary function testing systems market is classified into spirometry, exercise stress test, lung volume test, high altitude simulation testing, gas diffusion test, and other test types. The spirometry segment accounted for USD 1.3 billion in market revenue in 2024 and is anticipated to grow at a CAGR of 6.9% between 2025 to 2034 period.

• Spirometry is a fundamental test for diagnosing and monitoring respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. By measuring airflow and assessing lung function, it helps identify issues like airway obstruction, driving demand for spirometry systems in both clinical and home settings.
  
• Additionally, modern spirometry devices have become more accurate, user-friendly, and portable. Advances such as digital spirometers with touch-screen interfaces, wireless capabilities, and integration with health data platforms have made spirometry more appealing to both healthcare providers and patients.
  

Based on application, the pulmonary function testing systems market is classified into chronic obstructive pulmonary disease, asthma, chronic shortness of breath, pulmonary fibrosis, and other applications. The chronic obstructive pulmonary disease segment dominated the market in 2024 with a market share of 39.8%.

• COPD is one of the leading causes of morbidity and mortality globally, particularly in older adults and smokers. The growing number of COPD cases due to lifestyle factors (e.g., smoking and pollution) and an aging population is driving the demand for pulmonary function testing systems to monitor and manage the disease effectively.
  
• Further, there is a rising global emphasis on managing chronic diseases like COPD. Regular monitoring of lung function helps track the progression of COPD and adjust treatment plans accordingly. This is encouraging healthcare providers to adopt pulmonary function testing systems for consistent patient management.
  

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the pulmonary function testing systems market is segmented into hospitals & clinics, diagnostic centers, homecare settings, and other end users. The hospitals & clinics segment dominated the market in 2024 and is anticipated to reach USD 2.4 billion by the end of the forecast period.

• Hospitals and clinics are placing greater emphasis on preventive care and the early detection of respiratory conditions. Regular pulmonary function testing, such as spirometry, helps identify lung function abnormalities in their early stages, enabling timely intervention and improving patient outcomes.
  
• Furthermore, the adoption of advanced, user-friendly, and more accurate PFT systems in hospitals and clinics is on the rise. New devices with features like digital interfaces, wireless connectivity, and integration with electronic health records (EHR) are streamlining testing procedures, enhancing diagnostic accuracy, and improving patient care.
  

Looking for region specific data?

Download Free PDF

U.S. pulmonary function testing systems market accounted for USD 1.3 billion market revenue in 2024 and is anticipated to grow at a CAGR of 5.4% between 2025 to 2034 period.

• The U.S. is at the forefront of innovation in medical technologies. Advanced pulmonary function testing systems, such as digital spirometers and portable devices with wireless connectivity, are widely adopted across the country. These innovations make testing more accurate, efficient, and patient-friendly, thus increasing demand for these systems.
  
• Additionally, healthcare expenditure in the U.S. continues to increase, with diagnostic equipment remaining a key investment area. According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending grew by 2.7% in 2021, reaching USD 4.3 trillion, followed by a 4.1% increase in 2022 to USD 4.5 trillion. Healthcare facilities, including hospitals, clinics, and outpatient care centers, are investing in pulmonary function testing systems to enhance respiratory care services and improve patient outcomes.
  

Germany pulmonary function testing systems market is projected to grow remarkably in the coming years.

• Germany has a robust healthcare system with policies focused on the early detection and management of chronic diseases, including respiratory conditions. The government emphasis on preventive healthcare and routine screening encourages the use of pulmonary function testing systems for the early diagnosis and ongoing management of lung diseases.
  
• Furthermore, the country’s highly developed healthcare infrastructure includes state-of-the-art medical equipment in hospitals and clinics. The availability of advanced pulmonary function testing systems within this infrastructure supports the diagnosis and management of lung diseases, making these systems essential in clinical practice.
  

Japan holds a dominant position in the Asia Pacific pulmonary function testing systems market.

• Japan's medical technology sector has developed advanced pulmonary function testing systems, including digital spirometers and handheld devices. These systems are portable and user-friendly, offering improved accuracy and efficiency in clinical settings throughout Japan.
  
• For instance, according to the Japan Medical Devices Manufacturers Association (JMDA), investments in respiratory diagnostic equipment increased by 28% between 2021 and 2023. The Ministry of Health, Labour and Welfare reported that digital spirometer adoption in Japanese hospitals grew from 45% in 2021 to 72% in 2023, with projections reaching 85% by 2024.
  

Pulmonary Function Testing Systems Market Share

The market is marked by the presence of leading global players like Baxter, Philips, Fukuda Sangyo, and Schiller AG, among others. These companies focus on technological advancements such as portable and handheld spirometers, along with innovations in software for data integration and analysis.

Additionally, players are increasingly expanding their product portfolios to offer solutions for remote monitoring and home-based testing, driven by the rise in chronic respiratory conditions and the growing demand for non-invasive diagnostic tools. Partnerships and collaborations with hospitals and clinics are common strategies to strengthen market presence.

Pulmonary Function Testing Systems Market Companies

Prominent players operating in the pulmonary function testing systems industry include:

• Baxter
• CHEST M.I
• COSMED
• ECO MEDICS
• FUKUDA SANGYO
• GANSHORN SCHILLER GROUP
• Geratherm Respiratory
• medical equipment europe
• MGC DIAGNOSTICS
• MINATO MEDICAL SCIENCE
• MORGAN
• ndd Medical Technologies
• PHILIPS
• Vitalograph
• Vyaire MEDICAL
  

Pulmonary Function Testing Systems Industry News:

• In September 2024, Vitalograph announced the acquisition of Morgan Scientific, a respiratory diagnostics company. This acquisition may help the company in strengthening its U.S. commercial footprint and enabling it to meet the growing global demand for its innovative solutions, particularly in advanced pulmonary function testing solutions.
  
• In April 2021, Vyaire Medical announced the European launch of ArtiQ.PFT, an automated tool driven by artificial intelligence that instantly interprets pulmonary function tests (PFTs). This product launch positioned the company as a leader in innovative healthcare solutions, driving growth and reinforcing their commitment to advancing respiratory care.
  

The pulmonary function testing systems market research report includes in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Handheld
• Tabletop

Market, By Test Type

• Spirometry
• Exercise stress test
• Lung volume test
• High altitude simulation testing
• Gas diffusion test
• Other test types

Market, By Application

• Chronic obstructive pulmonary disease
• Asthma
• Chronic shortness of breath
• Pulmonary fibrosis
• Other applications

Market, By End Use

• Hospitals & clinics
• Diagnostic centers
• Homecare settings
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE